The Macroaxis Fundamental Analysis lookup allows users to check a given indicator for any equity or select from a set of available indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please check also Equity Screeners to view more equity screening tools
Probability Of Bankruptcy AnalysisFor stocks, Probability Of Bankruptcy is normalized value of Z-Score. For funds and ETFs it is derived from a multi-factor model developed by Macroaxis. The score is used to predict probability of a firm or a fund experiencing financial distress within next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100 indicating the actual probability the firm will be distressed in the next 2 fiscal years.
About Probability Of BankruptcyProbability of Bankruptcy SHOULD NOT be confused with actual chance of a company to file for chapter 7, 11, 12 or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty to meet its current financial obligations towards its creditors or to deliver on the expectations of its investors. Macroaxis derives these conditions on a daily bases from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns including short term and long term historical volatility. Other factors taken into account include analysis of liquidity, revenues patterns, R&D expenses and commitments, as well as public headlines and social sentiment.
|Compare to competition|
Based on latest financial disclosure Bharat Immunologicals Biologicals Corp Ltd has Probability Of Bankruptcy of 52%. This is 15.68% higher than that of the Healthcare sector, and 3.73% higher than that of Biotechnology industry, The Probability Of Bankruptcy for all stocks is 35.03% lower than the firm.
Bharat Immunologicals is rated below average in probability of bankruptcy category among related companies.
|Return On Equity||(10.18)%|
|Return On Asset||(9.86)%|
|Price to Earning||262.88X|
|Price to Book||1.47X|
|Price to Sales||1.62X|
|Cash and Equivalents||182.85M|
|Cash per Share||4.23X|
|Debt to Equity||3.80%|
|Book Value Per Share||7.91X|
|Earnings Per Share||(0.85)X|